Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer Inc. has signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.
You may also be interested in...
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.
Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local
Russia Premier Vladimir Putin has said he wants multinational pharmaceutical companies to manufacture drugs in Russia and support development of the local industry as part of a $4 billion government initiative to reform the Russia healthcare market by 2020. So perhaps it is not too surprising that both Novartis AG and AstraZeneca PLC chose to re-emphasize their commitments to Russia by each issuing press releases June 16 to coincide with the kickoff of the St. Petersburg International Economic Forum